Device-independent tool interprets corneal topography
September 15th 2004San Diego-There is a great variety of instruments and displays commercially available to assess corneal topography. The array of instrumentation makes it increasingly difficult to interpret corneal topography maps correctly. During the Innovator's Session of the recent annual meeting of the American Society of Cataract and Refractive Surgery, Stephen D. Klyce, PhD, introduced a device-independent neural network-based tool that automatically interprets corneal topography maps.
Sudden unilateral anterior uveitis is key to diagnosing spondyloarthropathies
September 15th 2004Portland, OR-Seronegative spondyloarthropathies are the most likely group of diseases that ophthalmologists will encounter in their practices, yet many cases will be overlooked if doctors rely on classic textbook definitions of symptoms, according to James T. Rosenbaum, MD, professor of ophthalmology and medicine, Casey Eye Institute, Oregon Health and Science University, Portland.
Verteporfin developer honored for research
September 15th 2004Vancouver, British Columbia-A research chemist from QLT Inc. who helped develop the verteporfin for injection (Visudyne, QLT/Novartis Ophthalmics) treatment for age-related macular degeneration is among 13 chemists from four companies who have been named Heroes of Chemistry by the American Chemical Society.
Intravenous agent safe, effective anti-angiogenic compound
September 15th 2004Fort Lauderdale, FL-Intravenous squalamine lactate being developed by Geneara Corp. shows promise as a safe and effective treatment for choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), according toresults of a phase I/II trial presented by Charles A. Garcia, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Medical liability: How does ophthalmology weigh in?
September 15th 2004The nation's medical liability crisis has yet to waver, according to the American Medical Association (AMA). With the addition of Massachusetts this summer, the AMA's official crisis chart is now composed of 20 states-up from 12 in 2002.
Implantable contact lenses used for wide range of myopia
September 1st 2004San Diego-Implantable contact lenses (ICLs) are safe and effective for treating a wide range of myopia, -3 to -20 D, based on the 3-year results from the U.S. multicenter Myopic Implantable Contact Lens Clinical Investigation. Donald R. Sanders, MD, PhD, presented the results at the American Society of Cataract and Refractive Surgery annual meeting.
Epithelial speciments viable 24 hours after epi-LASIK
September 1st 2004San Diego-Mechanically separated epithelial sheets following epi-LASIK appear to remain viable and retain their stratification 24 hours after the procedure, according to Vikentia J. Katsanevaki, MD, PhD, who spoke during the American Society of Cataract and Refractive Surgery annual meeting.
Wavefront-guided ablations help treat mixed astigmatism
September 1st 2004San Diego-Wavefront-guided ablations for the treatment of mixed astigmatism and/or high myopia using the CustomVue system (VISX, Santa Clara, CA) are providing good preliminary results, considering the challenge of treating these eyes with difficult refractions.
Iris-fixated lens effective for high myopia up to -20 D
September 1st 2004San Diego-The Artisan/Verisyse phakic IOL (Ophtec USA, AMO) fared well in preliminary analysis of data from one U.S. investigational center. It appears to be a safeand effective implant for use in patients with high myopia, according to Kerry Assil, MD, who spoke during the American Society of Cataract and Refractive Surgery annual meeting.
Study: custom LASIK, PRK superior to standard procedures
September 1st 2004San Diego-Early experience in a study that compared standard LASIK with LADARVision CustomCornea (Alcon Laboratories) to treat myopia with minimal astigmatism showed superior visual results with the customized LASIK and PRK procedures. The customized procedure induced about 0.25 D of against-the-rule astigmatism that resolved by 3 months.
Pattern, location top factors to evaluate in horizontal diplopia
September 1st 2004Ann Arbor, MI-When considering horizontal diplopia, two important factors are the pattern of the diplopia and the location. Wayne T. Cornblath, MD, described the clinical plan he follows when patients present with horizontal diplopia.
Ophthalmologists can play pivotal role in sarcoidosis care
September 1st 2004Irvine, CA-Sarcoidosis is a common cause of uveitis and one in which ophthalmologists can play a pivotal role by treating the disease and conferring with a patient's other physicians about its systemic manifestations, said Scott M. Whitcup, MD, assistant clinical professor of ophthalmology at the David Geffen School of Medicine at the University of California Los Angeles.
Comprehensive updates on retina, refractive, and glaucoma await ophthalmic delegates
September 1st 2004Don't miss "Ultimate Grand Rounds: Challenges in Cataract Surgery and Corneal Disease" (Sunday, Oct. 24, 10:40 a.m. to 12:10 p.m.), which is an exciting new session on cataract surgery and corneal disease. It will feature debates on case studies covering topics such as capsular tension rings, vitreous loss, multifocal IOLs, pterygium, herpes, dry eye, management of Fuchs' dystrophy, and cataract.
Added evidence points to importance of bone marrow-derived progenitor in CNV
September 1st 2004Fort Lauderdale, FL-Studies in a preclinical model of experimentally induced choroidal neovascularization (CNV) indicate that circulating bone marrow-derived cells contribute significantly to the vascular and inflammatory components of CNV. That finding has potential implications for understanding of the pathophysiology of CNV associated with age-related macular degeneration (AMD) as well as for suggesting new therapeutic targets, according to the researchers from the Bascom Palmer Eye Institute, University of Miami.